Q-omics provides the consensus-scored FAM126B profile across patient tissues and cancer cell-line models. FAM126B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM126B is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, FAM126B RNA expression shows 22,041 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where FAM126B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM126B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM126B survival associations across molecular data types. FAM126B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM126B RNA expression–survival associations across cancer types. High FAM126B expression shows unfavorable associations in ACC, UVM and LIHC, but favorable associations in KIRC, LUAD and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM126B RNA expression.
This table summarizes FAM126B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM126B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM126B shows lower tumor expression in COAD, THCA, KICH, KIRC, READ and KIRP. The COAD box plot shows higher FAM126B RNA expression in normal versus tumor tissue (log2 FC = −1.111, t-test p < 0.001).
This table shows molecular features associated with FAM126B in patient tissues and cancer cell lines. In patient samples, FAM126B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM126B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
